Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
The San Jose, California-based company has developed AccuScan, which analyzes a patient's circulating tumor DNA but does not require bespoke reagents.
Adaptive Biotechnologies Gets IVDR Class C Certification for ClonoSeq Assay
The certification makes the ClonoSeq assay available to EU patients and enables Adaptive to process EU clinical trial samples in its US laboratory.
Tempus AI, Personalis Expand Commercialization Partnership for MRD Test With $36M Investment
Tempus is the exclusive commercial partner for Personalis' minimal residual disease test for breast and lung cancers and for immunotherapy monitoring.
Guardant Health Q2 Revenues Grow 29 Percent; Firm Raises Full-Year Guidance
Guardant reached a major milestone in Q2 with the FDA approval of its Guardant Shield liquid biopsy colon cancer screening test.
Adaptive Biotechnologies Q2 Revenues Drop 12 Percent as MRD Revenues Soar
The Seattle-based company saw 36 percent growth in its minimal residual disease business while making significant progress in curbing operating expenses.